First Phase of Pradaxa Settlement Funds Ordered to Be Set Aside
As we reported earlier this year, Boehringer Ingelheim, the manufacturer of the blood-thinning drug Pradaxa, announced a $650 million deal to settle more than 2,000 lawsuits pending in multidistrict litigation.
Pradaxa (dabigatran) has been linked to fatal bleeding, digestive track ulcers, and brain hemorrhaging. Many people who have filed Pradaxa lawsuits alleged the drug caused massive bleeding, hemorrhaging, and atrial fibrillation. There have also been wrongful death lawsuits filed by the family members of loved ones who have allegedly died due to Pradaxa use.
U.S. District Judge David R. Herndon recently ordered that $561 million of the settlement funds be set aside for the first phase of payments, and $50 million be set aside for the second phase supplemental payments.
According to the National Law Journal, Herndon also ordered that $26 million be set aside to pay legal fees and $13 million for costs related to the work undertaken for the common benefit of the entire multidistrict litigation.
How Can I File a Pradaxa Lawsuit?
Earlier this year, the Institute for Safe Medication Practices (ISMP) reported that since 2010, Pradaxa use has resulted in more than 1,100 deaths and more than 12,000 injuries. When compared to the blood thinner Warfarin, Pradaxa has been linked to a 33 percent higher risk for fatal health problems.
For more information about Pradaxa litigation, contact our experienced pharmaceutical drug and device attorneys by calling toll-free 888-841-9623 today.
Zoll & Kranz, LLC – Defective Medical Drug and Device Lawyers